Cellular Immunotherapy Market Size, Share, Trends, Growth Outlook

Cellular Immunotherapy Market is estimated to increase at a growth rate of 17.9% CAGR over the forecast period from 2024 to 2030.

The Cellular Immunotherapy Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Type (CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy, Others), By Indication (B-cell Malignancies, Prostate Cancer, Liver Cancer, Renal Cell Carcinoma, Others), By End-User (Hospitals, Cancer Institutes, Others).

An Introduction to Cellular Immunotherapy Market in 2024

The Cellular Immunotherapy market in 2024 represents a transformative approach to cancer treatment harnessing the power of the immune system to target and destroy cancer cells. Cellular immunotherapy involves the administration of immune cells, such as T cells or natural killer cells, that have been genetically engineered or activated ex vivo to recognize and attack cancer cells. Market dynamics are driven by factors such as the increasing prevalence of cancer worldwide, advancements in immunotherapy research and technology, and the demand for personalized and targeted cancer treatments. Collaboration between immunologists, oncologists, biotechnology companies, and regulatory agencies drives innovation and accessibility in cellular immunotherapy, offering new hope for patients with refractory or relapsed cancers.

Cellular Immunotherapy Market Trend: Advancements in Chimeric Antigen Receptor (CAR) T-cell Therapy

A prominent trend in the Cellular Immunotherapy market is the advancements in Chimeric Antigen Receptor (CAR) T-cell therapy. CAR T-cell therapy has emerged as a groundbreaking approach for treating various hematological malignancies and solid tumors by harnessing the power of the immune system to target cancer cells. Recent innovations in CAR T-cell engineering, including next-generation CAR designs, novel target antigens, and optimized manufacturing processes, have led to improved treatment outcomes, expanded indications, and enhanced patient access to cellular immunotherapies. This trend is driving the rapid adoption and development of CAR T-cell therapies across the oncology landscape.

Cellular Immunotherapy Market Driver: Growing Demand for Personalized Cancer Therapies

The primary driver for the Cellular Immunotherapy market is the growing demand for personalized cancer therapies. Cellular immunotherapies, such as CAR T-cell therapy and Tumor-Infiltrating Lymphocyte (TIL) therapy, offer a personalized treatment approach that targets specific antigens expressed by individual patients' tumors. With the increasing recognition of the heterogeneity of cancer and the limitations of conventional treatments, there is a significant shift towards personalized medicine paradigms that tailor therapies to the unique genetic and immunological profiles of patients. This growing demand for personalized cancer therapies is fueling investments in cellular immunotherapy research, clinical trials, and commercialization efforts.

Cellular Immunotherapy Market Opportunity: Development of Off-the-Shelf Allogeneic Cell Therapies

An opportunity in the Cellular Immunotherapy market lies in the development of off-the-shelf allogeneic cell therapies. While autologous cellular immunotherapies have demonstrated remarkable efficacy in certain cancer types, they are limited by patient-specific manufacturing timelines, logistical challenges, and high costs. Off-the-shelf allogeneic cell therapies, derived from healthy donor cells, have the potential to overcome these limitations by providing readily available, standardized, and cost-effective treatments that can be administered to a broader patient population. By investing in research and development efforts focused on allogeneic cell therapies, companies can capitalize on the opportunity to expand the reach and accessibility of cellular immunotherapies, address scalability challenges, and accelerate the development and commercialization of next-generation cancer treatments.

Cellular Immunotherapy Market Segmentation

By Therapy Type
CAR T Cell Therapy
Dendritic Cell Therapy
NK Cell Therapy
TIL Therapy
Others
By Indication
B-cell Malignancies
Prostate Cancer
Liver Cancer
Renal Cell Carcinoma
Others
By End User
Hospitals
Cancer Institutes
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

 

Cellular Immunotherapy Market Companies

Adicet Bio Inc
AstraZeneca
Bristol-Myers Squibb Company
Celyad
Dendreon Pharmaceuticals LLC
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc (Kite Pharma)
GlaxoSmithKline plc
Johnson & Johnson
Merck KGaA
Novartis AG
Pfizer Inc

 

 

Reasons to Buy the Cellular Immunotherapy Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Cellular Immunotherapy Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Cellular Immunotherapy Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

 

TABLE OF CONTENTS

1 Introduction to 2024 Cellular Immunotherapy Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Cellular Immunotherapy Market Size Outlook, $ Million, 2021 to 2030
3.2 Cellular Immunotherapy Market Outlook by Type, $ Million, 2021 to 2030
3.3 Cellular Immunotherapy Market Outlook by Product, $ Million, 2021 to 2030
3.4 Cellular Immunotherapy Market Outlook by Application, $ Million, 2021 to 2030
3.5 Cellular Immunotherapy Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Cellular Immunotherapy Market Industry
4.2 Key Market Trends in Cellular Immunotherapy Market Industry
4.3 Potential Opportunities in Cellular Immunotherapy Market Industry
4.4 Key Challenges in Cellular Immunotherapy Market Industry

5 Market Factor Analysis
5.1 Competitive Landscape
5.1.1 Global Cellular Immunotherapy Market Share by Company (%), 2023
5.1.2 Product Offerings by Company
5.2 Porter’s Five Forces Analysis

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Cellular Immunotherapy Market Outlook By Segments
7.1 Cellular Immunotherapy Market Outlook by Segments
By Therapy Type
CAR T Cell Therapy
Dendritic Cell Therapy
NK Cell Therapy
TIL Therapy
Others
By Indication
B-cell Malignancies
Prostate Cancer
Liver Cancer
Renal Cell Carcinoma
Others
By End User
Hospitals
Cancer Institutes
Others

8 North America Cellular Immunotherapy Market Analysis And Outlook To 2030
8.1 Introduction to North America Cellular Immunotherapy Markets in 2024
8.2 North America Cellular Immunotherapy Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Cellular Immunotherapy Market size Outlook by Segments, 2021-2030
By Therapy Type
CAR T Cell Therapy
Dendritic Cell Therapy
NK Cell Therapy
TIL Therapy
Others
By Indication
B-cell Malignancies
Prostate Cancer
Liver Cancer
Renal Cell Carcinoma
Others
By End User
Hospitals
Cancer Institutes
Others

9 Europe Cellular Immunotherapy Market Analysis And Outlook To 2030
9.1 Introduction to Europe Cellular Immunotherapy Markets in 2024
9.2 Europe Cellular Immunotherapy Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Cellular Immunotherapy Market Size Outlook By Segments, 2021-2030
By Therapy Type
CAR T Cell Therapy
Dendritic Cell Therapy
NK Cell Therapy
TIL Therapy
Others
By Indication
B-cell Malignancies
Prostate Cancer
Liver Cancer
Renal Cell Carcinoma
Others
By End User
Hospitals
Cancer Institutes
Others

10 Asia Pacific Cellular Immunotherapy Market Analysis And Outlook To 2030
10.1 Introduction to Asia Pacific Cellular Immunotherapy Markets in 2024
10.2 Asia Pacific Cellular Immunotherapy Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Cellular Immunotherapy Market size Outlook by Segments, 2021-2030
By Therapy Type
CAR T Cell Therapy
Dendritic Cell Therapy
NK Cell Therapy
TIL Therapy
Others
By Indication
B-cell Malignancies
Prostate Cancer
Liver Cancer
Renal Cell Carcinoma
Others
By End User
Hospitals
Cancer Institutes
Others

11 South America Cellular Immunotherapy Market Analysis And Outlook To 2030
11.1 Introduction to South America Cellular Immunotherapy Markets in 2024
11.2 South America Cellular Immunotherapy Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Cellular Immunotherapy Market size Outlook by Segments, 2021-2030
By Therapy Type
CAR T Cell Therapy
Dendritic Cell Therapy
NK Cell Therapy
TIL Therapy
Others
By Indication
B-cell Malignancies
Prostate Cancer
Liver Cancer
Renal Cell Carcinoma
Others
By End User
Hospitals
Cancer Institutes
Others

12 Middle East And Africa Cellular Immunotherapy Market Analysis And Outlook To 2030
12.1 Introduction to Middle East and Africa Cellular Immunotherapy Markets in 2024
12.2 Middle East and Africa Cellular Immunotherapy Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Cellular Immunotherapy Market size Outlook by Segments, 2021-2030
By Therapy Type
CAR T Cell Therapy
Dendritic Cell Therapy
NK Cell Therapy
TIL Therapy
Others
By Indication
B-cell Malignancies
Prostate Cancer
Liver Cancer
Renal Cell Carcinoma
Others
By End User
Hospitals
Cancer Institutes
Others

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Adicet Bio Inc
AstraZeneca
Bristol-Myers Squibb Company
Celyad
Dendreon Pharmaceuticals LLC
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc (Kite Pharma)
GlaxoSmithKline plc
Johnson & Johnson
Merck KGaA
Novartis AG
Pfizer Inc

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Therapy Type
CAR T Cell Therapy
Dendritic Cell Therapy
NK Cell Therapy
TIL Therapy
Others
By Indication
B-cell Malignancies
Prostate Cancer
Liver Cancer
Renal Cell Carcinoma
Others
By End User
Hospitals
Cancer Institutes
Others